Altimmune to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022:

• H.C. Wainwright Global Investment ConferenceTuesday, May 24, 20227:00 am Eastern TimeThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

• B. Riley Securities Institutional Investor ConferenceThursday, May 26, 20221:00 pm Pacific TimeThe session will be an in person fireside chat.

About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Richard EisenstadtChief Financial OfficerPhone: 240-654-1450[email protected]

You May Also Be Interested In

• EdgeMode and BlackBerry AIF Sign Memorandum of Understanding to Create BLACK AI, a Publicly Listed AI Infrastructure Development Platform
• Parks Associates to Explore AI's Role in Transforming Multifamily Operations at Smart Spaces, Sept. 15-16, in Dallas/Plano, Texas
• Energy volatility could fast-track global EV adoption to 50% above base case, Wood Mackenzie finds